HIGHLIGHTS
- who: Girolamo Ranieri and colleagues from the Nuclear Medicine Unit, University of Bari "Aldo Moro", Bari, Italy have published the research: Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation, in the Journal: (JOURNAL)
- what: The study suggests that TKIs can be used in the treatment of advanced RCC regardless of the metastatic site, and that FDG PET/CT is a useful method of surveillance to monitor therapeutic response in all lesions.
- future: It has been suggested that a new assessment . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.